DPP-4 inhibitors × cardiovascular events

Observational studyEuropean heart journal2023

Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study.

Edouard L Fu et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 2023

Not counted

Probably reduced cardiovascular events

−28%−33% to −23%

Bigger than 6 in 10 for cardiovascular events

As reported

HR 0.72, 95% CI 0.67–0.77

One number in the abstract

the abstract, start to end

outcome [adjusted hazard ratio (HR) 0.72; 95% confidence interval

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 0.720.67–0.77
SGLT2 inhibitorsDPP-4 inhibitorsCardiovascular events
1 / 3

13 papers cite it

2023
2024
2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 37259575